BIOASTER

About the company

BIOASTER is the first Institute for Technological Innovation in Microbiology in France (Lyon and Paris, Pasteur Institute). They are Non-for-profit Technology Research Institute, active in the field of vaccine, immunomodulation, microbiota, anti-infectives, and IVD.
With BIOASTER, each project benefits from the right scientific and technology mix to address specific issues, quality in execution to meet high-standard requirements and case-by-case financial risk-sharing partnerships.
Their industrial partners come from a wide range of industries, including pharma, biotech, animal health, nutrition and diagnostics.

About the solution

Examples of partnership themes include for vaccine : Memory response /Longitudinal study, Efficacy, Memory response /Longitudinal study,correlate of protection, Breadth of protection, benchmarking with competitives vaccines, vaccine & adjuvant MOA, Exploratory research, preclinical & clinical biomarkers identification, system serology, immunometabolism (immunophenotyping at single cell), microbiota & immunity, host pathogen interaction.

Examples of partnership themes include for bioprocess- bioproduction & CMC: biomarkers identification for batch success/batch failure, digital tween & machine learning/deep Learning, method development & benchmarking, antigen characterization, potency assays development, Host Cell Proteins identification, CMC methods for in vitro mRNA production, mRNA formulation.

Website

Key information

– Therapeutic areas: Infectious & therapeutic vaccines, Immunology, Auto-immune diseases, Inflammatory diseases, Immuno-modulation, Microbiota, Antimicrobial, Antiviral, Ivd, Support to bioprocess optimization & bioproduction, Support to cmc

– Based in: Paris & Lyon (FRANCE)

– Employees: 51 – 200

– Created in: 2012

TEMISIS

About the company

Temisis, a preclinical-stage biotechnology company, is developing innovative therapeutics for patients living with chronic inflammatory and auto-immune diseases, with a primary focus on psoriasis. Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications.

They believe that TEM2085, exhibiting significant efficacy in animal models of immuno-inflammatory diseases and resulting from our drug discovery platform, has the potential to show comparable efficacy to biologics which have demonstrated to date the greatest therapeutic benefit in this area. Temisis’ short-term goal is to move TEM2085 through final stages of preclinical development for clinical evaluation.

About the solution

Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications. In vitro, TEM2085 shows, at low concentrations, significant inhibition of NFKBIZ expression induced by IL-17/TNFα in keratinocytes. In vivo, TEM2085 has demonstrated in rodent models, at a lower dose, greater therapeutic benefit than the TYK2 inhibitor deucravacitinib against psoriasis and strong protection against ulcerative colitis. By targeting NFKBIZ signaling, TEM2085 and its analogues have the potential to address various immunological disorders.

Website

Key information

– Therapeutic areas: Inflammatory diseases, Auto-immune diseases

– Based in: Vandœuvre-lès-Nancy (FRANCE)

– Employees: 1-10

– Created in: 2017